228 related articles for article (PubMed ID: 34275048)
1. Molecular Testing for Thyroid Nodules Including Its Interpretation and Use in Clinical Practice.
Patel SG; Carty SE; Lee AJ
Ann Surg Oncol; 2021 Dec; 28(13):8884-8891. PubMed ID: 34275048
[TBL] [Abstract][Full Text] [Related]
2. ACR TI-RADS and ATA US scores are helpful for the management of thyroid nodules with indeterminate cytology.
Barbosa TLM; Junior COM; Graf H; Cavalvanti T; Trippia MA; da Silveira Ugino RT; de Oliveira GL; Granella VH; de Carvalho GA
BMC Endocr Disord; 2019 Oct; 19(1):112. PubMed ID: 31664992
[TBL] [Abstract][Full Text] [Related]
3. Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: a retrospective chart review.
Hier J; Avior G; Pusztaszeri M; Krasner JR; Alyouha N; Forest VI; Hier MP; Mlynarek A; Richardson K; Sadeghi N; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2021 Apr; 50(1):29. PubMed ID: 33910629
[TBL] [Abstract][Full Text] [Related]
4. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
5. An update on the status of molecular testing for the indeterminate thyroid nodule and risk stratification of differentiated thyroid cancer.
Nicholson KJ; Yip L
Curr Opin Oncol; 2018 Jan; 30(1):8-15. PubMed ID: 29028645
[TBL] [Abstract][Full Text] [Related]
6. Molecular Testing for Indeterminate Thyroid Nodules: Association of Negative Predictive Value With Nodule Size.
Barnes AB; Justice-Clark T; Li W; Randle RW
Am Surg; 2022 Nov; 88(11):2745-2751. PubMed ID: 35723175
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal Assessment of Quality of Life Following Molecular Testing for Indeterminate Thyroid Nodules.
Schumm MA; Nguyen DT; Kim J; Tseng CH; Chow AY; Shen N; Livhits MJ
Ann Surg Oncol; 2021 Dec; 28(13):8872-8881. PubMed ID: 34292427
[TBL] [Abstract][Full Text] [Related]
8. Thyroid Nodule Molecular Testing: Is It Ready for Prime Time?
Khan TM; Zeiger MA
Front Endocrinol (Lausanne); 2020; 11():590128. PubMed ID: 33162941
[TBL] [Abstract][Full Text] [Related]
9. How Effective is the Use of Molecular Testing in Preoperative Decision Making for Management of Indeterminate Thyroid Nodules?
Steinmetz D; Kim M; Choi JH; Yeager T; Samuel K; Khajoueinejad N; Buseck A; Imtiaz S; Fernandez-Ranvier G; Lee D; Owen R; Taye A
World J Surg; 2022 Dec; 46(12):3043-3050. PubMed ID: 36167834
[TBL] [Abstract][Full Text] [Related]
10. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.
Shrestha RT; Evasovich MR; Amin K; Radulescu A; Sanghvi TS; Nelson AC; Shahi M; Burmeister LA
Thyroid; 2016 Aug; 26(8):1068-76. PubMed ID: 27283257
[TBL] [Abstract][Full Text] [Related]
11. Cost analysis of reflexive versus selective molecular testing for indeterminate thyroid nodules.
Hu QL; Schumm MA; Zanocco KA; Yeh MW; Livhits MJ; Wu JX
Surgery; 2022 Jan; 171(1):147-154. PubMed ID: 34284895
[TBL] [Abstract][Full Text] [Related]
12. Association of Tumor Size With Histologic and Clinical Outcomes Among Patients With Cytologically Indeterminate Thyroid Nodules.
Valderrabano P; Khazai L; Thompson ZJ; Otto KJ; Hallanger-Johnson JE; Chung CH; Centeno BA; McIver B
JAMA Otolaryngol Head Neck Surg; 2018 Sep; 144(9):788-795. PubMed ID: 30027226
[TBL] [Abstract][Full Text] [Related]
13. The Role of Molecular Testing for the Indeterminate Thyroid FNA.
Rossi ED; Pantanowitz L; Faquin WC
Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31547603
[TBL] [Abstract][Full Text] [Related]
14. The incidental thyroid nodule.
Fisher SB; Perrier ND
CA Cancer J Clin; 2018 Mar; 68(2):97-105. PubMed ID: 29369334
[TBL] [Abstract][Full Text] [Related]
15. Clinical Experience of Cytologically Indeterminate Thyroid Nodules Designated as Negative on Molecular Testing Using ThyroSeq V3: A Retrospective Cohort Study.
Corriveau-Parenteau E; Turkdogan S; Noik M; Forest VI; da Silva SD; Pusztaszeri M; Abdulhaleem M; Hier MP; Richardson K; Sadeghi N; Payne RJ
Thyroid; 2023 May; 33(5):641-644. PubMed ID: 36825531
[No Abstract] [Full Text] [Related]
16. Risk stratification of indeterminate thyroid nodules by novel multigene testing: a study of Asians with a high risk of malignancy.
Hu C; Jing W; Chang Q; Zhang Z; Liu Z; Cao J; Zhao L; Sun Y; Wang C; Zhao H; Xiao T; Guo H
Mol Oncol; 2022 Apr; 16(8):1680-1693. PubMed ID: 35247035
[TBL] [Abstract][Full Text] [Related]
17. Molecular-Directed Treatment of Differentiated Thyroid Cancer: Advances in Diagnosis and Treatment.
Yip L; Sosa JA
JAMA Surg; 2016 Jul; 151(7):663-70. PubMed ID: 27223483
[TBL] [Abstract][Full Text] [Related]
18. A Novel Risk Stratification System for Thyroid Nodules With Indeterminate Cytology-A Pilot Cohort Study.
Gomes-Lima CJ; Auh S; Thakur S; Zemskova M; Cochran C; Merkel R; Filie AC; Raffeld M; Patel SB; Xi L; Wartofsky L; Burman KD; Klubo-Gwiezdzinska J
Front Endocrinol (Lausanne); 2020; 11():53. PubMed ID: 32132976
[No Abstract] [Full Text] [Related]
19. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules.
Beaudenon-Huibregtse S; Alexander EK; Guttler RB; Hershman JM; Babu V; Blevins TC; Moore P; Andruss B; Labourier E
Thyroid; 2014 Oct; 24(10):1479-87. PubMed ID: 24811481
[TBL] [Abstract][Full Text] [Related]
20. National differences in cost analysis of Afirma Genomic sequencing classifier.
Ronen O; Oichman M
Clin Endocrinol (Oxf); 2021 Apr; 94(4):717-724. PubMed ID: 33349964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
